-The Indian Express Government privileges the private over the public, preferring trade to health In a dramatic development, US industry groups recently claimed the Indian government offered them a “private” assurance that compulsory licences will not be issued, save in emergencies and for non-commercial purposes. Needless to state, such an assurance flies in the face of the Patents Act and the public health safeguards enshrined in it. Illustratively, Section 84 mandates that...

-The Times of India Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes. Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile,...

-Live Mint Incidents at Bhopal and Indore highlight irregularities and ethical violations in some trials In 2004, doctors at the Bhopal Memorial Hospital and Research Centre (BMHRC), established exclusively for treating the victims of the 1984 gas leak, recruited unsuspecting survivors for clinical trials without their knowledge or consent; 14 participants died during the course of the trials. Together with the episode in Indore’s Maharaja Yashwantrao Hospital (that Mint reported on 10...

-The Business Standard The proposed pharma pricing policy may give room to drug makers to escape price control. While the policy is primarily aimed at making essential medicines affordable, many feel the spirit is missing in the recommendations put forward by a group of ministers a few days ago. For instance, the ministerial panel has proposed to regulate prices of only 348 essential medicines and keep combination products out of control —...

Fighting cancer has just become less expensive for millions of Indian patients. More than 12 years after he electrified the pharma industry by taking on powerful global giants in his quest to supply cheap anti-AIDS drugs, Cipla promoter YK Hamied is back donning the role of a price warrior. This time, his attention is on anti-cancer drugs. On Thursday, Cipla cut prices of key cancer drugs by nearly 75%, an astounding,...